Press Releases

BioMarin Pharmaceutical Inc and Deep Genomics announced that the companies have entered into a preclinical collaboration that will use Deep Genomics' artificial intelligence drug discovery platform (The AI Workbench) to identify oligonucleotide drug candidates in four rare disease indications with high unmet need.  Deep Genomics will receive an undisclosed upfront payment and is eligible to receive development milestones as a part of the collaboration.  BioMarin will receive an

Tris Pharma, Inc. ("Tris"), a specialty pharmaceutical company with a robust portfolio of FDA-approved products for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) and related disorders, and Medison Pharma ("Medison"), a leading international commercial partner for highly innovative therapies, announced  that they have entered into an agreement whereby Medison received exclusive rights to commercialize Tris' FDA-approved Quillivant XR in Israel.

RefleXion Medical, a therapeutic oncology company pioneering biology-guided radiotherapy* (BgRT) as a new modality for treating all stages of cancer, announced its first multi-system contract with Integrated Proton Solutions (IPS), a provider of turn-key proton therapy programs in the United States. The multi-year, multi-site contract will create centers that house both of these advanced approaches to external beam radiotherapy (EBRT) for treating malignant tumors. “IPS looks

Amylyx Pharmaceuticals, Inc., a pharmaceutical company focused on developing new treatments for amyotrophic lateral sclerosis (ALS), Alzheimer’s disease and other neurodegenerative diseases, announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to AMX0035 for the treatment of Wolfram syndrome. “There is a critical unmet need for people living with Wolfram syndrome, a rare genetic disease in which many patients die prematurely with

CPhI & P-MEC China returns as a hybrid event  in Shanghai (16-18 December, 2020), with a physical exhibition running alongside Virtual Expo Connect(18 November – 18 December, 2020) for international audiences unable to attend. The physical exhibition will be held at the SNIEC (Shanghai New International Expo Center), with some 3,000 exhibitors present across three days, alongside exhibitor talks and conferences. Crucially, this year’s exhibition will support int

RAPT Therapeutics, Inc., a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in oncology and inflammatory diseases, announced that the Company plans to present initial data from its Phase 1/2 clinical trial of FLX475 in patients with multiple cancer indications in a premarket press release and webcast on Monday, November 16, 2020. RAPT will host a c

Selva Therapeutics, Inc. announced that the company has received U.S. Food and Drug Administration (FDA) clearance of an Investigational New Drug (IND) application for SLV213 for the treatment of COVID-19 and has dosed the first subjects in a Phase 1 clinical study. Selva also announced preclinical data demonstrating in several host cell models that SLV213 inhibits SARS-CoV-2 infection by blocking the human host cell cysteine protease called cathepsin L (CTSL). “These data pro

Aligos Therapeutics, Inc., a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, today announced that its Belgian subsidiary Aligos Belgium BV has been awarded a €1.8M grant by the Flemish Agency for Innovation and Entrepreneurship (VLAIO) to support a nonclinical research project related to combination therapy for Hepatitis B at Aligos (CoHeBA). “CoHeBA aims to elucidate the mechani

Rousselot, a Darling Ingredients brand and the global leader of collagen-based solutions[1], announces the development of its latest SiMoGelTM concept for center-filled gummies. This gelatin-based solution improves process efficiency and flexibility for a faster, cost-effective and hygienic production of nutraceutical and pharmaceutical gummies. With this latest innovation within the SiMoGelTM range, brands can develop innovative center-filled soft-gummies − also named “gummy caps

FUJIFILM Cellular Dynamics, Inc., a leading global developer and manufacturer of human induced pluripotent stem cells (iPSC) technologies, and Lonza Walkersville, Inc. (Lonza, a leading global GMP iPSC manufacturer), have entered into a worldwide agreement. The agreement enables drug developers to leverage both companies' expertise and technologies for the generation of iPSCs through licensing agreements. Under the agreement, FUJIFILM Cellular Dynamics grants Lonza a non-exclusi